BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev 2019;28:190021. [PMID: 31484664 DOI: 10.1183/16000617.0021-2019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Wu Z, Liu Y, Zhan Z, Yang L, Wang C, Jiang Q, Ran H, Li P, Wang Z. ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling. J Nanobiotechnology 2022;20:213. [PMID: 35524280 DOI: 10.1186/s12951-022-01435-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Liu J, Gu L, Li W. The Prognostic Value of Integrated Analysis of Inflammation and Hypoxia-Related Genes in Idiopathic Pulmonary Fibrosis. Front Immunol 2022;13:730186. [PMID: 35309336 DOI: 10.3389/fimmu.2022.730186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022;205:e18-47. [PMID: 35486072 DOI: 10.1164/rccm.202202-0399ST] [Cited by in Crossref: 39] [Cited by in F6Publishing: 1] [Article Influence: 39.0] [Reference Citation Analysis]
4 Filidou E, Kandilogiannakis L, Tarapatzi G, Spathakis M, Steiropoulos P, Mikroulis D, Arvanitidis K, Paspaliaris V, Kolios G. Anti-Inflammatory and Anti-Fibrotic Effect of Immortalized Mesenchymal-Stem-Cell-Derived Conditioned Medium on Human Lung Myofibroblasts and Epithelial Cells. Int J Mol Sci 2022;23:4570. [PMID: 35562961 DOI: 10.3390/ijms23094570] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang X, Yang J, Wu L, Tong C, Zhu Y, Cai W, Wan B, Zhang X. Adiponectin inhibits the activation of lung fibroblasts and pulmonary fibrosis by regulating the nuclear factor kappa B (NF-κB) pathway. Bioengineered 2022;13:10098-110. [DOI: 10.1080/21655979.2022.2063652] [Reference Citation Analysis]
6 Yao Y, Li Z, Gao W. Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and NSCLC Progression:Evidence From Bioinformatics Analysis. Front Genet 2022;13:855789. [DOI: 10.3389/fgene.2022.855789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 To S, Chavula T, Pedroza M, Smith J, Agarwal SK. Cadherin-11 Regulates Macrophage Development and Function. Front Immunol 2022;13:795337. [PMID: 35211116 DOI: 10.3389/fimmu.2022.795337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rinaldi S, Balsillie C, Truchon C, Al‐mubarak A, Mura M, Madill J. Nutrition implications of intrinsic restrictive lung disease. Nut in Clin Prac. [DOI: 10.1002/ncp.10849] [Reference Citation Analysis]
9 Li XZ, Wang XL, Wang YJ, Liang QK, Li Y, Chen YW, Ming HX. Total flavonoids of Oxytropis falcata Bunge have a positive effect on idiopathic pulmonary fibrosis by inhibiting the TGF-β1/Smad signaling pathway. J Ethnopharmacol 2022;285:114858. [PMID: 34826543 DOI: 10.1016/j.jep.2021.114858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sklepkiewicz P, Dymek BA, Mlacki M, Koralewski R, Mazur M, Nejman-Gryz P, Korur S, Zagozdzon A, Rymaszewska A, von der Thüsen JH, Siwińska AM, Güner NC, Cheda Ł, Paplinska-Goryca M, Proboszcz M, van den Bosch TPP, Górska K, Golab J, Kamiński RM, Krenke R, Golebiowski A, Dzwonek K, Dobrzanski P. Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis. Eur J Pharmacol 2022;:174792. [PMID: 35122869 DOI: 10.1016/j.ejphar.2022.174792] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, Reiss AB. Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J 2022;16:84-96. [PMID: 35001525 DOI: 10.1111/crj.13466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Mei Q, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis. Front Pharmacol 2022;12:797292. [DOI: 10.3389/fphar.2021.797292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Velagacherla V, Mehta CH, Nayak Y, Nayak UY. Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis. Life Sci 2022;291:120283. [PMID: 34998839 DOI: 10.1016/j.lfs.2021.120283] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Avci E, Sarvari P, Savai R, Seeger W, Pullamsetti SS. Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets? Int J Mol Sci 2022;23:546. [PMID: 35008971 DOI: 10.3390/ijms23010546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Li G, He H, Zheng G, Jiang W, Du S, Tao H, Xiao T, Zhou D, Ding S, Yu X, Zhang Y, Shen A. Direct Detection of Pulmonary Fibrosis by Near-Infrared-Responsive Biomimetic Platelets. IJN 2022;Volume 17:151-62. [DOI: 10.2147/ijn.s334331] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Dogan AB, Rohner NA, Smith JNP, Kilgore JA, Williams NS, Markowitz SD, von Recum HA, Desai AB. Polymer Microparticles Prolong Delivery of the 15-PGDH Inhibitor SW033291. Pharmaceutics 2021;14:85. [PMID: 35056981 DOI: 10.3390/pharmaceutics14010085] [Reference Citation Analysis]
17 Kim SK, Jung SM, Park KS, Kim KJ. Integrative analysis of lung molecular signatures reveals key drivers of idiopathic pulmonary fibrosis. BMC Pulm Med 2021;21:404. [PMID: 34876074 DOI: 10.1186/s12890-021-01749-3] [Reference Citation Analysis]
18 Yang M, Dong J, An J, Liu L, Chen L. Effect of anti-reflux therapy on pulmonary function in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. J Thorac Dis 2021;13:5776-87. [PMID: 34795926 DOI: 10.21037/jtd-21-771] [Reference Citation Analysis]
19 Fanidis D, Moulos P, Aidinis V. Fibromine is a multi-omics database and mining tool for target discovery in pulmonary fibrosis. Sci Rep 2021;11:21712. [PMID: 34741074 DOI: 10.1038/s41598-021-01069-w] [Reference Citation Analysis]
20 Han Y, Jiang M, He R, Lv X, Liao X, He Y, Zhang F, Long L, Jiang G, Peng Z, Tao L, Hu G, Meng J. Mefunidone Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice. Front Pharmacol 2021;12:713572. [PMID: 34630088 DOI: 10.3389/fphar.2021.713572] [Reference Citation Analysis]
21 Cassidy N, Fox L, Love M, Byrne I, Doyle AM, Korn B, Shanagher D, Shone T, Cullen M, Cullen T, Mullaney P, O'Carroll N, O'Dowd G, O'Sullivan T, Russell AM. Fibrotic interstitial lung disease - palliative care needs: a World-Café qualitative study. BMJ Support Palliat Care 2021:bmjspcare-2021-003249. [PMID: 34635541 DOI: 10.1136/bmjspcare-2021-003249] [Reference Citation Analysis]
22 Maqhuzu PN, Kreuter M, Bahmer T, Kahn N, Claussen M, Holle R, Schwarzkopf L. Cost drivers in the pharmacological treatment of interstitial lung disease. Respir Res 2021;22:218. [PMID: 34344376 DOI: 10.1186/s12931-021-01807-8] [Reference Citation Analysis]
23 Redente EF. How Do We Know What We Are Missing? Loss of Signaling through CD148 Drives Fibroblast Activation in Pulmonary Fibrosis. Am J Respir Crit Care Med 2021;204:249-51. [PMID: 33891825 DOI: 10.1164/rccm.202103-0737ED] [Reference Citation Analysis]
24 Roman J, Chiba H. B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents. Am J Respir Cell Mol Biol 2021;64:652-4. [PMID: 33725473 DOI: 10.1165/rcmb.2021-0101ED] [Reference Citation Analysis]
25 Farrand E, Limper AH. Clinical Trials for Idiopathic Pulmonary Fibrosis and the Role of Health Systems. Clin Chest Med 2021;42:287-94. [PMID: 34024404 DOI: 10.1016/j.ccm.2021.03.006] [Reference Citation Analysis]
26 Wang X, Ren R, Xu Z, Huang H, Jiang W, Ma J. Tirbanibulin Attenuates Pulmonary Fibrosis by Modulating Src/STAT3 Signaling. Front Pharmacol 2021;12:693906. [PMID: 34349652 DOI: 10.3389/fphar.2021.693906] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Kai Y, Yoneyama H, Yoshikawa M, Kimura H, Muro S. Chondroitin sulfate in tissue remodeling: Therapeutic implications for pulmonary fibrosis. Respir Investig 2021;59:576-88. [PMID: 34176780 DOI: 10.1016/j.resinv.2021.05.012] [Reference Citation Analysis]
28 Doni A, Mantovani A, Bottazzi B, Russo RC. PTX3 Regulation of Inflammation, Hemostatic Response, Tissue Repair, and Resolution of Fibrosis Favors a Role in Limiting Idiopathic Pulmonary Fibrosis. Front Immunol 2021;12:676702. [PMID: 34276664 DOI: 10.3389/fimmu.2021.676702] [Reference Citation Analysis]
29 Mattoo H, Pillai S. Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions. Cell Mol Life Sci 2021;78:5527-42. [PMID: 34145462 DOI: 10.1007/s00018-021-03874-y] [Reference Citation Analysis]
30 Wang J, Ren Y, Zheng X, Kang J, Huang Z, Xu L, Wang Y. Anti-Fibrotic Effects of Low Toxic Microcystin-RR on Bleomycin-Induced Pulmonary Fibrosis: A Comparison with Microcystin-LR. Front Pharmacol 2021;12:675907. [PMID: 34168562 DOI: 10.3389/fphar.2021.675907] [Reference Citation Analysis]
31 Ye Z, Hu Y. TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review). Int J Mol Med 2021;48:132. [PMID: 34013369 DOI: 10.3892/ijmm.2021.4965] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Li S, Xu A, Li Y, Tan C, La Regina G, Silvestri R, Wang H, Qi W. RS4651 suppresses lung fibroblast activation via the TGF-β1/SMAD signalling pathway. Eur J Pharmacol 2021;903:174135. [PMID: 33940030 DOI: 10.1016/j.ejphar.2021.174135] [Reference Citation Analysis]
33 Bradbury P, Nader CP, Cidem A, Rutting S, Sylvester D, He P, Rezcallah MC, O'Neill GM, Ammit AJ. Tropomyosin 2.1 collaborates with fibronectin to promote TGF-β1-induced contraction of human lung fibroblasts. Respir Res 2021;22:129. [PMID: 33910572 DOI: 10.1186/s12931-021-01730-y] [Reference Citation Analysis]
34 Hadda V, Guleria R. Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know? Indian J Med Res 2020;152:177-80. [PMID: 33107479 DOI: 10.4103/ijmr.IJMR_90_20] [Reference Citation Analysis]
35 Albacete-Albacete L, Sánchez-Álvarez M, Del Pozo MA. Extracellular Vesicles: An Emerging Mechanism Governing the Secretion and Biological Roles of Tenascin-C. Front Immunol 2021;12:671485. [PMID: 33981316 DOI: 10.3389/fimmu.2021.671485] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Fabbri L, Jones S. Changing priorities for pulmonary fibrosis: the patient will see you now! Thorax 2021;76:534-5. [PMID: 33790003 DOI: 10.1136/thoraxjnl-2020-216616] [Reference Citation Analysis]
37 Piñeiro-Hermida S, Autilio C, Martínez P, Bosch F, Pérez-Gil J, Blasco MA. Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging. J Cell Biol 2020;219:e202002120. [PMID: 32777016 DOI: 10.1083/jcb.202002120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
38 Llamazares-Prada M, Espinet E, Mijošek V, Schwartz U, Lutsik P, Tamas R, Richter M, Behrendt A, Pohl ST, Benz NP, Muley T, Warth A, Heußel CP, Winter H, Landry JJM, Herth FJ, Mertens TC, Karmouty-Quintana H, Koch I, Benes V, Korbel JO, Waszak SM, Trumpp A, Wyatt DM, Stahl HF, Plass C, Jurkowska RZ. Versatile workflow for cell type-resolved transcriptional and epigenetic profiles from cryopreserved human lung. JCI Insight 2021;6:140443. [PMID: 33630765 DOI: 10.1172/jci.insight.140443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Kreuter M, Ladner UM, Costabel U, Jonigk D, Heussel CP. The Diagnosis and Treatment of Pulmonary Fibrosis. Dtsch Arztebl Int 2021;118:arztebl. [PMID: 33531115 DOI: 10.3238/arztebl.m2021.0018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Cao X, Li Y, Shi J, Tang H. The Potentially Therapeutic Role of EPAC in Curbing the Process of Idiopathic Pulmonary Fibrosis via Differential Cellular Pathways. J Inflamm Res 2021;14:611-9. [PMID: 33679138 DOI: 10.2147/JIR.S296382] [Reference Citation Analysis]
41 Sundaresan L, Giri S, Singh H, Chatterjee S. Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action. Br J Clin Pharmacol 2021;87:3835-50. [PMID: 33609410 DOI: 10.1111/bcp.14792] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Mao Y, Jacob V, Singal A, Lei S, Park MS, Lima MRN, Li C, Dhall S, Sathyamoorthy M, Kohn J. Exosomes Secreted from Amniotic Membrane Contribute to Its Anti-Fibrotic Activity. Int J Mol Sci 2021;22:2055. [PMID: 33669673 DOI: 10.3390/ijms22042055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Yap JMG, Ueda T, Kanemitsu Y, Takeda N, Fukumitsu K, Fukuda S, Uemura T, Tajiri T, Ohkubo H, Maeno K, Ito Y, Oguri T, Ugawa S, Niimi A. AITC inhibits fibroblast-myofibroblast transition via TRPA1-independent MAPK and NRF2/HO-1 pathways and reverses corticosteroids insensitivity in human lung fibroblasts. Respir Res 2021;22:51. [PMID: 33579280 DOI: 10.1186/s12931-021-01636-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Antoniou KM, Tsitoura E, Vasarmidi E, Symvoulakis EK, Aidinis V, Tzilas V, Tzouvelekis A, Bouros D. Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care. Curr Opin Pharmacol 2021;57:71-80. [PMID: 33556824 DOI: 10.1016/j.coph.2020.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
45 Hannan RT, Miller AE, Hung RC, Sano C, Peirce SM, Barker TH. Extracellular matrix remodeling associated with bleomycin-induced lung injury supports pericyte-to-myofibroblast transition. Matrix Biol Plus 2021;10:100056. [PMID: 34195593 DOI: 10.1016/j.mbplus.2020.100056] [Reference Citation Analysis]
46 Löfdahl A, Tornling G, Wigén J, Larsson-Callerfelt AK, Wenglén C, Westergren-Thorsson G. Pathological Insight into 5-HT2B Receptor Activation in Fibrosing Interstitial Lung Diseases. Int J Mol Sci 2020;22:E225. [PMID: 33379351 DOI: 10.3390/ijms22010225] [Reference Citation Analysis]
47 Jandl K, Kwapiszewska G. Stiffness of the Extracellular Matrix: A Regulator of Prostaglandins in Pulmonary Fibrosis? Am J Respir Cell Mol Biol 2020;63:721-2. [PMID: 32946267 DOI: 10.1165/rcmb.2020-0398ED] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Checa J, Aran JM. Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology. Int J Mol Sci 2020;21:E9317. [PMID: 33297418 DOI: 10.3390/ijms21239317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
49 Ikeda K, Chiba H, Nishikiori H, Azuma A, Kondoh Y, Ogura T, Taguchi Y, Ebina M, Sakaguchi H, Miyazawa S, Suga M, Sugiyama Y, Nukiwa T, Kudoh S, Takahashi H; Pirfenidone Clinical Study Group in Japan. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respir Res 2020;21:316. [PMID: 33256760 DOI: 10.1186/s12931-020-01582-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
50 Beck H, Thaler T, Meibom D, Meininghaus M, Jörißen H, Dietz L, Terjung C, Bairlein M, von Bühler CJ, Anlauf S, Fürstner C, Stellfeld T, Schneider D, Gericke KM, Buyck T, Lovis K, Münster U, Anlahr J, Kersten E, Levilain G, Marossek V, Kast R. Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). J Med Chem 2020;63:11639-62. [PMID: 32969660 DOI: 10.1021/acs.jmedchem.0c00834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Cruwys S, Hein P, Humphries B, Black D. Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities. Drug Discov Today 2020;25:2277-83. [PMID: 33010480 DOI: 10.1016/j.drudis.2020.09.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
52 Togami K, Maruta Y, Nanbu M, Tada H, Chono S. Prolonged distribution of aerosolized PEGylated liposomes in the lungs of mice with bleomycin-induced pulmonary fibrosis. Drug Dev Ind Pharm 2020;46:1873-80. [PMID: 32940095 DOI: 10.1080/03639045.2020.1825473] [Reference Citation Analysis]
53 Lan Y, Wu D, Jin Y, Shui M, Fan X. Danhong injection in the treatment of idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22016. [PMID: 32925734 DOI: 10.1097/MD.0000000000022016] [Reference Citation Analysis]
54 Yang J, Hu H, Zhang S, Jiang L, Cheng Y, Xie H, Wang X, Jiang J, Wang H, Zhang Q. [Human umbilical cord mesenchymal stem cell-derived exosomes alleviate pulmonary fibrosis in mice by inhibiting epithelial-mesenchymal transition]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:988-94. [PMID: 32895166 DOI: 10.12122/j.issn.1673-4254.2020.07.11] [Reference Citation Analysis]
55 Fang L, Chen H, Kong R, Que J. Endogenous tryptophan metabolite 5-Methoxytryptophan inhibits pulmonary fibrosis by downregulating the TGF-β/SMAD3 and PI3K/AKT signaling pathway. Life Sci 2020;260:118399. [PMID: 32918977 DOI: 10.1016/j.lfs.2020.118399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Leung EL, Pan HD, Huang YF, Fan XX, Wang WY, He F, Cai J, Zhou H, Liu L. The Scientific Foundation of Chinese Herbal Medicine against COVID-19. Engineering (Beijing) 2020;6:1099-107. [PMID: 33520331 DOI: 10.1016/j.eng.2020.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
57 Caporarello N, Meridew JA, Aravamudhan A, Jones DL, Austin SA, Pham TX, Haak AJ, Moo Choi K, Tan Q, Haresi A, Huang SK, Katusic ZS, Tschumperlin DJ, Ligresti G. Vascular dysfunction in aged mice contributes to persistent lung fibrosis. Aging Cell 2020;19:e13196. [PMID: 32691484 DOI: 10.1111/acel.13196] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
58 Zhang F, Ayaub EA, Wang B, Puchulu-Campanella E, Li YH, Hettiarachchi SU, Lindeman SD, Luo Q, Rout S, Srinivasarao M, Cox A, Tsoyi K, Nickerson-Nutter C, Rosas IO, Low PS. Reprogramming of profibrotic macrophages for treatment of bleomycin-induced pulmonary fibrosis. EMBO Mol Med 2020;12:e12034. [PMID: 32597014 DOI: 10.15252/emmm.202012034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
59 Caliskan C, Seeliger B, Jäger B, Fuge J, Welte T, Terwolbeck O, Freise J, van Moorsel CHM, Zhang Y, Prasse A. Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis-Part B. J Clin Med 2020;9:E1993. [PMID: 32630441 DOI: 10.3390/jcm9061993] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Wiertz IA, Moll SA, Seeliger B, Barlo NP, van der Vis JJ, Korthagen NM, Rijkers GT, Ruven HJT, Grutters JC, Prasse A, van Moorsel CHM. Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. J Clin Med 2020;9:E1940. [PMID: 32575869 DOI: 10.3390/jcm9061940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
61 Barczi E, Nagy T, Starobinski L, Kolonics-Farkas A, Eszes N, Bohacs A, Tarnoki AD, Tarnoki DL, Müller V. Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival. Thorac Cancer 2020;11:1911-7. [PMID: 32401433 DOI: 10.1111/1759-7714.13481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Rønnow SR, Dabbagh RQ, Genovese F, Nanthakumar CB, Barrett VJ, Good RB, Brockbank S, Cruwys S, Jessen H, Sorensen GL, Karsdal MA, Leeming DJ, Sand JMB. Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis. Respir Res 2020;21:108. [PMID: 32381012 DOI: 10.1186/s12931-020-01369-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
63 Sgalla G, Flore M, Siciliano M, Richeldi L. Antibody-based therapies for idiopathic pulmonary fibrosis. Expert Opin Biol Ther 2020;20:779-86. [PMID: 32098521 DOI: 10.1080/14712598.2020.1735346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
64 Valenzuela C, Torrisi SE, Kahn N, Quaresma M, Stowasser S, Kreuter M. Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. Respir Res 2020;21:7. [PMID: 31906942 DOI: 10.1186/s12931-019-1269-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
65 Cottin V. Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. Eur Respir Rev 2019;28:190109. [PMID: 31578213 DOI: 10.1183/16000617.0109-2019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
66 Harari S, Adir Y, Humbert M. Rare pulmonary disease and orphan drugs: a path to the future. Eur Respir Rev 2019;28:190115. [PMID: 31578214 DOI: 10.1183/16000617.0115-2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]